Last $50.55 USD
Change Today +0.15 / 0.30%
Volume 4.3M
MYL On Other Exchanges
Symbol
Exchange
Munich
As of 8:10 PM 07/30/14 All times are local (Market data is delayed by at least 15 minutes).

mylan inc (MYL) Snapshot

Open
$50.77
Previous Close
$50.40
Day High
$50.96
Day Low
$49.89
52 Week High
03/4/14 - $57.52
52 Week Low
07/31/13 - $33.20
Market Cap
18.9B
Average Volume 10 Days
4.9M
EPS TTM
$2.02
Shares Outstanding
373.7M
EX-Date
07/17/07
P/E TM
25.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for MYLAN INC (MYL)

mylan inc (MYL) Details

Mylan Inc., a pharmaceutical company, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. It operates in two segments, Generics and Specialty. The Generics segment primarily provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch form, as well as active pharmaceutical ingredients (APIs). This segment is also involved in developing APIs with non-infringing processes to partner with manufacturers; and the manufacture and sale of injectable products in the therapeutic areas of antineoplastics, anti-infectives, anesthesia/pain management, and cardiovascular. In addition, it produces finished dosage form (FDF) products for the antiretroviral (ARV) market and non-ARV FDF products that are marketed to third parties. This segment serves proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The Specialty segment manufactures and sells branded specialty injectable and nebulized products comprising EpiPen Auto-Injector for the treatment of severe allergic reactions; and Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients. It also offers ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia. This segment serves pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. Mylan Inc. has a strategic collaboration with Pfizer Japan Inc. to develop, manufacture, distribute and market generic drugs in Japan. The company was formerly known as Mylan Laboratories Inc. and changed its name to Mylan Inc. in October 2007. Mylan Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

20,000 Employees
Last Reported Date: 02/27/14
Founded in 1961

mylan inc (MYL) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: $1.1M
President, Director and Member of Science & T...
Total Annual Compensation: $840.4K
Executive Chairman and Chairman of Executive ...
Total Annual Compensation: $1.4M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $650.0K
Compensation as of Fiscal Year 2013.

mylan inc (MYL) Key Developments

Seven Companies Sign Sub-Licensing Agreements with Medicines Patent Pool

Seven subcontracts have been signed licensing agreements with the Switzerland-based Medicines Patent Pool (MPP) to manufacture two antiretroviral drugs. The agreements involve Aurobindo, Emcure (both India), and Desano (China) manufacturing a generic version of Bristol Myers Squibb (BMS, US)'s atazanavir. The manufacturers, including Cipla, Laurus Labs, Micro Labs (all three India), and Mylan (US), have also signed agreements to manufacture ViiV Healthcare (UK)'s dolutegravir. BMS added atazanavir to the MPP in December 2013 and ViiV Healthcare included dolutegravir in the pool in April.

Sanofi Reportedly In Talks With Buyers For Sale Of Drug Portfolio

Sanofi (ENXTPA:SAN) has held talks with Abbott Laboratories (NYSE:ABT), Mylan, Inc. (NasdaqGS:MYL) and private equity firms for the possible sale of a €6.3 billion portfolio of mature drugs, according to an internal document seen by Reuters.

Abbott Laboratories, Mylan, Inc. - M&A Call

To discuss the definitive agreement to acquire Abbott's non-U.S. developed markets specialty and branded generics business in an all-stock transaction

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYL:US $50.55 USD +0.15

MYL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Omnicare Inc $63.40 USD +0.14
Perrigo Co PLC $153.89 USD -0.75
UCB SA €69.89 EUR +3.23
WW Grainger Inc $240.03 USD +1.29
WESCO International Inc $80.34 USD -0.42
View Industry Companies
 

Industry Analysis

MYL

Industry Average

Valuation MYL Industry Range
Price/Earnings 31.4x
Price/Sales 2.7x
Price/Book 5.9x
Price/Cash Flow 29.8x
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYLAN INC, please visit www.mylan.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.